Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
Abstract
The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus disease-2019 (COVID-19), has swept the world in unprecedented speed. In a few months, SARS-CoV-2 has infected millions of people and caused tens of thousands of deaths. There are no Food and Drug Administration-approved antivirals or vaccines yet available and clinical treatments are limited to supportive therapies that help alleviate the symptoms. Thus, there is an urgent need to identify effective antivirals as countermeasures before safe and effective vaccines are developed, tested, and then produced on a large scale. Our approach is to harness the germline-encoded interferon antiviral response to inhibit SARS-CoV-2 replication thereby limiting its pathogenicity.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 25, 2020
- Source ID
- 10.1073/pnas.2012197117
Entities
People
- Abhinav Diwan
- Alex J. B. Kreutzberger
- Daved H. Fremont
- Eylan Yutuc
- Gaopeng Hou
- Haitao Guo
- Haiyan Zhao
- Hu Zhang
- James Brett Case
- Juhee Son
- Kartik Mani
- María Florencia Gómez Castro
- Michael D. Vahey
- Michael S. Diamond
- Paul W Rothlauf
- Qiru Zeng
- Ruochen Zang
- Sayantan Bose
- Sean P J Whelan
- Sheng Shen
- Siyuan Ding
- Tomas Kirchhausen
- William J Griffiths
- Xin Wang
- Xiucui Ma
- Yuqin Wang
- Zhuoming Liu
Organizations
- Biotechnology and Biological Sciences Research Council
- Boston Children's Hospital
- Harvard Medical School
- Helen Hay Whitney Foundation
- Indiana University School of Medicine
- John Cochran VA Medical Center
- Ministry of Education of the People's Republic of China
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- Swansea University
- Washington University School of Medicine
- Washington University in St. Louis